Strongbridge Biopharma plc Announces Last Patient Completes Last Study Visit in the Randomized Withdrawal Phase of the LOGICS Trial Evaluating RECORLEV® (levoketoconazole) for Endogenous Cushing’s Syndrome
Dublin, Ireland and Trevose, Pa., July 1, 2020 – Strongbridge Biopharma (Nasdaq: SBBP) announced that the last participant has completed the randomized withdrawal phase of the LOGICS study for RECORLEV® (levoketoconazole), aimed at treating endogenous Cushing’s syndrome, with 43 patients involved. The company expects to report topline data in Q3 2020 and plans to submit a New Drug Application (NDA) to the FDA approximately six months after the results. The ongoing clinical programs, including SONICS and LOGICS, have shown promising outcomes for RECORLEV.
- Completion of 43 patient visits in LOGICS study enhances data collection.
- Topline data reporting expected in Q3 2020, signaling progress.
- SONICS study achieved primary and secondary endpoints, showing significant results.
- Potential risks and uncertainties related to clinical trials and regulatory approval.
- Dependence on positive outcomes from the LOGICS study for NDA submission.
DUBLIN, Ireland and TREVOSE, Pa., July 01, 2020 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the last participant has completed the last study visit in the randomized withdrawal phase of the LOGICS study for RECORLEV® (levoketoconazole), its product candidate for the treatment of endogenous Cushing’s syndrome. A total of 43 patients completed the randomized withdrawal phase of the study.
“We are very pleased to have accomplished this important clinical milestone for RECORLEV® (levoketoconazole) and look forward to reporting topline data in the third quarter of this year,” said Fredric Cohen, M.D., chief medical officer of Strongbridge Biopharma. “We are very grateful to the investigators, the patients, and their families for working together during the unprecedented global COVID-19 pandemic to make this study possible – moving us one step closer to the possibility of bringing this next-generation treatment to people with endogenous Cushing’s syndrome.”
The Phase 3 program for RECORLEV consists of SONICS and LOGICS: two multinational studies designed to evaluate the safety and efficacy of RECORLEV when used to treat endogenous Cushing’s syndrome. The SONICS study met its primary and secondary endpoints, demonstrating a statistically significant normalization rate of urinary free cortisol at six months. The LOGICS study is a double-blind, placebo-controlled randomized-withdrawal study of RECORLEV that is designed to supplement the long-term efficacy and safety information supplied by SONICS. The Company plans to submit a New Drug Application (NDA) for RECORLEV to the FDA approximately six months after reporting topline LOGICS results.
About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge’s rare endocrine franchise includes RECORLEV® (levoketoconazole), a cortisol synthesis inhibitor currently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing’s syndrome, and veldoreotide extended release, a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation. Both RECORLEV and veldoreotide have received orphan drug designation from the FDA and the European Medicines Agency. The Company’s rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the United States.
About RECORLEV
RECORLEV® (levoketoconazole) is an investigational cortisol synthesis inhibitor in development for the treatment of patients with endogenous Cushing’s syndrome, a rare but serious and potentially lethal endocrine disease caused by chronic elevated cortisol exposure. RECORLEV is the pure 2S,4R enantiomer of ketoconazole, a steroidogenesis inhibitor. RECORLEV is believed to significantly suppress serum cortisol in healthy subjects and has the potential to be a next-generation cortisol inhibitor.
The Phase 3 program for RECORLEV consists of SONICS and LOGICS: two multinational studies designed to evaluate the safety and efficacy of RECORLEV when used to treat endogenous Cushing’s syndrome. The SONICS study met its primary and secondary endpoints, demonstrating a statistically significant normalization rate of urinary free cortisol at six months. The ongoing LOGICS study is a double-blind, placebo-controlled randomized-withdrawal study of RECORLEV that is designed to supplement the long-term efficacy and safety information supplied by SONICS.
RECORLEV has received orphan drug designation from the FDA and the European Medicines Agency for the treatment of endogenous Cushing's syndrome.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. The words “anticipate,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “will,” “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. All statements, other than statements of historical facts, contained in this press release, are forward-looking statements, including statements related to the status of clinical trials, the release of top-line data from the LOGICS study and the submission of an NDA for RECORLEV to the FDA, and Strongbridge’s strategy, plans and objectives of management for future operations. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in such statement, including risks and uncertainties associated with clinical development and the regulatory approval process, the reproducibility of any reported results showing the benefits of RECORLEV, the adoption of RECORLEV by physicians, if approved, as treatment for any disease and the emergence of unexpected adverse events following regulatory approval and use of the product by patients. Additional risks and uncertainties relating to Strongbridge and its business can be found under the heading “Risk Factors” in Strongbridge’s Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent filings with the SEC. These forward-looking statements are based on current expectations, estimates, forecasts and projections and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors. The forward-looking statements contained in this press release are made as of the date of this press release, and Strongbridge Biopharma does not assume any obligation to update any forward-looking statements except as required by applicable law.
Contacts:
Corporate and Media Relations
Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
lrocco@elixirhealthpr.com
Investor Relations
Solebury Trout
Mike Biega
+1 617-221-9660
mbiega@soleburytrout.com
FAQ
What recent milestone did Strongbridge Biopharma achieve for SBBP?
When will Strongbridge report topline data for the LOGICS study?
What is the purpose of the LOGICS study for SBBP?
What are the primary results from the SONICS study related to SBBP?
What regulatory action is Strongbridge Biopharma planning for RECORLEV®?
